









Markets
/
Stocks
/
nasdaq-vvos
/

Vivos Therapeutics Inc

VVOS

1.550USD

+0.050+3.33%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

12.81MMarket Cap

LossP/E TTM



Vivos Therapeutics Inc

1.550

+0.050+3.33%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Vivos Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Vivos Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 104 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Vivos Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

104 / 205

Overall Ranking

281 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Vivos Therapeutics Inc Highlights

StrengthsRisks

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.

Growing

The company is in a growing phase, with the latest annual income totaling USD 15.03M.

Fairly Valued

The company’s latest PE is -0.87, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.30M shares, increasing 27.84% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 304.16K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

5.000

Target Price

+233.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Vivos Therapeutics Inc is 6.98, ranking 113 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 6.78M, representing a year-over-year increase of 75.73%, while its net profit experienced a year-over-year increase of 106.42%.

Score

Industry at a Glance

Previous score

6.98

Change



Financials

5.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.60

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

5.24

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.63

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.42

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Vivos Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Vivos Therapeutics Inc is 8.23, ranking 36 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.87, which is -83.57% below the recent high of -0.14 and -581.00% above the recent low of -5.96.

Score

Industry at a Glance

Previous score

8.23

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Vivos Therapeutics Inc is 7.33, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 5.50, with a high of 7.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

5.000

Target Price

+233.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Vivos Therapeutics Inc

VVOS

Stryker Corp

SYK

Dexcom Inc

DXCM

Abbott Laboratories

ABT

Medtronic PLC

MDT

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Vivos Therapeutics Inc is 5.49, ranking 177 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 2.12 and the support level at 1.20, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.42

Change

0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.047

Sell

RSI(14)

33.041

Neutral

STOCH(KDJ)(9,3,3)

23.757

Neutral

ATR(14)

0.140

Low Volatility

CCI(14)

-80.034

Neutral

Williams %R

81.020

Oversold

TRIX(12,20)

-1.246

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.538

Buy

MA10

1.613

Sell

MA20

1.795

Sell

MA50

1.998

Sell

MA100

2.428

Sell

MA200

3.087

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Vivos Therapeutics Inc is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 13.73%, representing a quarter-over-quarter increase of 26.30%. The largest institutional shareholder is The Vanguard, holding a total of 304.16K shares, representing 3.22% of shares outstanding, with 345.20% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Skaff (Michael C.)

828.00K

Luo (Dawei)

572.02K

V-CO Investors, L.L.C.

514.50K

The Vanguard Group, Inc.

Star Investors

91.46K

+114.53%

Armistice Capital LLC

250.28K

Intracoastal Capital, L.L.C.

228.61K

Connective Capital Management, LLC

200.00K

Strategic Wealth Investment Group, LLC

100.00K

Ionic Ventures LLC

83.00K

Huntsman (Ronald Kirk)

73.06K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Vivos Therapeutics Inc is 2.69, ranking 147 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 6.89. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.